» Articles » PMID: 38332941

Opioid Use Disorder: Current Trends and Potential Treatments

Overview
Specialty Public Health
Date 2024 Feb 9
PMID 38332941
Authors
Affiliations
Soon will be listed here.
Abstract

Opioid use disorder (OUD) is a major public health threat, contributing to morbidity and mortality from addiction, overdose, and related medical conditions. Despite our increasing knowledge about the pathophysiology and existing medical treatments of OUD, it has remained a relapsing and remitting disorder for decades, with rising deaths from overdoses, rather than declining. The COVID-19 pandemic has accelerated the increase in overall substance use and interrupted access to treatment. If increased naloxone access, more buprenorphine prescribers, greater access to treatment, enhanced reimbursement, less stigma and various harm reduction strategies were effective for OUD, overdose deaths would not be at an all-time high. Different prevention and treatment approaches are needed to reverse the concerning trend in OUD. This article will review the recent trends and limitations on existing medications for OUD and briefly review novel approaches to treatment that have the potential to be more durable and effective than existing medications. The focus will be on promising interventional treatments, psychedelics, neuroimmune, neutraceutical, and electromagnetic therapies. At different phases of investigation and FDA approval, these novel approaches have the potential to not just reduce overdoses and deaths, but attenuate OUD, as well as address existing comorbid disorders.

Citing Articles

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.

Valdez T, Patel V, Senesombath N, Hatahet-Donovan Z, Hornick M Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598395 PMC: 11597566. DOI: 10.3390/ph17111484.


Synergistic Epistasis and Systems Biology Approaches to Uncover a Pharmacogenomic Map Linked to Pain, Anti-Inflammatory and Immunomodulating Agents (PAIma) in a Healthy Cohort.

Sharafshah A, Motovali-Bashi M, Keshavarz P, Blum K Cell Mol Neurobiol. 2024; 44(1):74.

PMID: 39505757 PMC: 11541314. DOI: 10.1007/s10571-024-01504-2.


Role of serotonin neurons in the dorsal raphe nucleus in heroin self-administration and punishment.

Li C, McCloskey N, Inan S, Kirby L Neuropsychopharmacology. 2024; 50(3):596-604.

PMID: 39300273 PMC: 11735851. DOI: 10.1038/s41386-024-01993-1.


Patterns and Emerging Trends in Acute Poisoning with Substances of Abuse Used for Recreational Purposes in Adolescents: A Six-Year Multicentre Study.

Turcu T, Lescaie A, Grama A, Stratula A, Vincene A, Grigoras L Life (Basel). 2024; 14(8).

PMID: 39202775 PMC: 11355456. DOI: 10.3390/life14081033.


High-throughput label-free opioid receptor binding assays using an automated desorption electrospray ionization mass spectrometry platform.

Feng Y, Morato N, Huang K, Lin M, Cooks R Chem Commun (Camb). 2024; 60(63):8224-8227.

PMID: 39007214 PMC: 11293027. DOI: 10.1039/d4cc02346c.


References
1.
Namba M, Leyrer-Jackson J, Nagy E, Olive M, Neisewander J . Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities. Front Neurosci. 2021; 15:650785. PMC: 8082184. DOI: 10.3389/fnins.2021.650785. View

2.
Gold M, Baron D, Bowirrat A, Blum K . Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?. J Neurol Sci. 2020; 418:117137. PMC: 7490287. DOI: 10.1016/j.jns.2020.117137. View

3.
Abulseoud O, Camsari U, Ruby C, Kasasbeh A, Choi S, Choi D . Attenuation of ethanol withdrawal by ceftriaxone-induced upregulation of glutamate transporter EAAT2. Neuropsychopharmacology. 2014; 39(7):1674-84. PMC: 4023140. DOI: 10.1038/npp.2014.14. View

4.
Fantegrossi W, Murnane K, Reissig C . The behavioral pharmacology of hallucinogens. Biochem Pharmacol. 2007; 75(1):17-33. PMC: 2247373. DOI: 10.1016/j.bcp.2007.07.018. View

5.
Blum K, Thompson B, Demotrovics Z, Femino J, Giordano J, Oscar-Berman M . The Molecular Neurobiology of Twelve Steps Program & Fellowship: Connecting the Dots for Recovery. J Reward Defic Syndr. 2015; 1(1):46-64. PMC: 4545669. DOI: 10.17756/jrds.2015-008. View